SB-T-101141
SB-T-101141 is a novel taxane. SB-T-101141 effectively induces a noncanonical ferroptosis to overcome Paclitaxel (HY-B0015) resistance of breast cancer. SB-T-101141 facilitates the production of iron and ferrous ions and ROS. SB-T-101141 stably binds to KHSRP to inhibit the iron-dependent expression of CISD1 related to iron homeostasis. SB-T-101141 synergistically enhances the iron-dependent activation of JNK and PERK pathways via KHSRP. SB-T-101141 suppresses breast tumor growth in MCF-7(PR)/MDA-MB-231(PR) or KHSRP knock-down MCF-7 xenograft mice model.
For research use only. We do not sell to patients.
- CAS No.: 186348-05-0
- Formula: C44H55NO17
- Molecular Weight:869.90
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
66.66 nM
Compound: 31; SB-T-101141
|
Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay
|
[PMID: 29468872] |
In Vitro
SB-T-101141 (1-3 μM, 12 h) efficiently induces microtubule polymerization and tubulin protein expression in MCF-7 and MDA-MB-453 cells[1].
SB-T-101141 (1-3 μM, 72 h) has potent cytotoxicity with IC50 of 0.03, 0.8 and 6.5 μM for MCF-7, MDA-MB-453 and MDA-MB-231 cells, respectively, while similar effect on normal MCF-10A cells[1].
SB-T-101141 (0.001-8 μM, 1-14 days) strongly inhibits cell proliferation and colony formation, and increased cell death in MCF-7 and MDA-MB-453 cells[1].
SB-T-101141 (9 μM, 5 days) effectively inhibits the growth of patient breast cancer organoids[1].
SB-T-101141 (1-8 μM, 12-60 h) significantly induces cell apoptosis and G2/M phase arrest at 1 μM (no efficacy at high dose), without level changes of cleavages of PARP and caspase-7 in MCF-7 and MDA-MB-453 cells[1].
SB-T-101141 (3-16 μM, 4-72 h) induces a ferroptosis-like cell death morphology with a low accumulation and increase of membrane permeability, and this effect is markedly blocked by Z-VAD-FMK and Necrostatin-1, with a mild effect on mitochondria numbers and ATP level in MCF-7 and MDA-MB-453 cells[1].
SB-T-101141 (0.17-8 μM, 0-48 h) significantly increases intracellular iron and ferrous ion as well as MDA level, and reduces GSH level without obvious effect on GPX4 expression in MCF-7, MDA-MB-453 and MCF-7PR cells[1].
SB-T-101141 (0.17-16 μM, 3-48 h) induces the total ROS (neutralized by DFOM and NAC), lipid ROS, membrane permeability the impaired cell viability and cell death, not be attenuated by DFOM, Fer-1, or Lip-1, in MCF-7, MDA-MB-453, MCF-7PR and MDA-MB-453PR cells[1].
SB-T-101141 (3-5 nM, 14 days) significantly inhibits Paclitaxel-resistant MCF-7PR and MDA-MB-231PR cells proliferation[1].
SB-T-101141 (0.25-1.5 μM, 24 h) induces Paclitaxel-resistant cell death and this effect is only only efficiently inhibited by iron chelators DFOM and CPX in MCF-7PR and MDA-MB-453PR cells[1].
SB-T-101141(0.001-3 μM, 1-14 days) is more sensitive to MCF-7 cellular with knocking down KHSRP than knocking down HDGF and CYP2S1[1].
SB-T-101141 (0.01-100 μM, 2-24 h) enhances the thermal stability of KHSRP protein without influence on KHSRP expression in MCF-7 cells[1].
SB-T-101141 (1.5-3 μM, 0-24 h) promotes lipid peroxidation and effectively reduced the mRNA and protein level of CISD1while increase of 4-HNE level via KHSRP in MCF-7 and MCF-7PR cells[1].
SB-T-101141 (10 μM, 4 h) prominently exertes ER stress-related G3BP1 granule aggregation, without affecting G3BP1 expression[1].
SB-T-101141 (0.17-16 μM, 24-48 h) increases protein level of eIF2α and induces cell death via the iron-dependent JNK and PERK signaling with in MCF-7, MDA-MB-453, MCF-7PR and MDA-MB-231PR cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7 cells, MDA-MB-453 cells
-
Concentration:3 μM (MCF-7 cells), 8 μM (MDA-MB-453 cells)
-
Incubation Time:12, 24, 36, 48, 60, 72 h
-
Result:Efficiently increased cell death in MCF-7 and MDA-MB-453 cells.
Induced cell death but this effect was reversed by apoptosis inhibitor (Z-VAD-FMK) (HY-16658B) and necrosis inhibitor (Necrostatin-1) (HY-15760).
Significantly increased Paclitaxel-resistant MCF-7PR and MDA-MB-231PR cells survival with IC50 of 2.7 and 0.235 μM, respectively.
-
Cell Line:MCF-7 cells, MDA-MB-453 cells
-
Concentration:1 μM
-
Incubation Time:12 h
-
Result:Efficiently induced microtubule polymerization.
-
Cell Line:MCF-7 cells, MDA-MB-453 cells
-
Concentration:1,3 5 μM (MCF-7 cells), 8 μM (MDA-MB-453 cells)
-
Incubation Time:12, 24, 36, 48, 60 h
-
Result:Significantly increased the tubulin protein expression in MCF-7 cells at 12 h.
Induced no cleavages of PARP and caspase-7 protein expression changes during 12-60 h in MCF-7 and MDA-MB-453 cells.
-
Cell Line:MCF-7 cells, MDA-MB-453 cells
-
Concentration:1 nM, 2 μM (MCF-7 cells), 1 nM, 5 μM (MDA-MB-453 cells)
-
Incubation Time:1, 14 days
-
Result:Significantly decreased cell proliferation at 1 day in MCF-7 and MDA-MB-453 cells.
Strongly inhibited colony formation at 1 nM after 14 days in MCF-7 and MDA-MB-453 cells.
-
Cell Line:MCF-7 cells, MDA-MB-453 cells
-
Concentration:1 μM
-
Incubation Time:48 h
-
Result:Significantly induced cell apoptosis with late apoptosis population from 7.38% to 17.81% in MCF-7 cells and MDA-MB-453 cells (10.51% to 30.76%).
-
Cell Line:MCF-7 cells, MDA-MB-453 cells
-
Concentration:1,3 μM (MCF-7 cells), 1,8 μM (MDA-MB-453 cells)
-
Incubation Time:24 h
-
Result:Significantly induced G2/M phase arrest with G2/M phase population from 11.67% and 9.26% to 23.02% and 28.37% at 1 μM in MCF-7 and MDA-MB-453 cells, respectively.
Induced no G2/M phase arrest at high dose of 3 and 8 μM in MCF-7 and MDA-MB-453 cells, respectively.
In Vivo
SB-T-101141 (5 mg/kg, i.p., once every three days) induces no inhibitory activity in tumor growth without increase of aldehyde 4-HNE level in KHSRP knock-down MCF-7 xenografted mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female immune-deficient BALB/c nude mice (4 weeks old) were injected subcutaneously with Estradiol cypionate (HY-B1100) following with MCF-7 cells (5 × 106 cells/mouse) or MDA-MB-453 cells (1 × 107 cells/mouse)[1].
-
Dosage:5 mg/kg, Estradiol cypionate (1.5 mg/kg)
-
Administration:i.p., once every three days (Estradiol cypionate, once every seven days) and then measured body weight and tumor volume.
-
Result:Strongly repressed tumor growth in MCF-7/ MDA-MB-453 xenografted tumor mice model.
Caused no significant mouse body weight changes in MDA-MB-453 xenografted tumor mice model.
Had a strong antitumor effect on the Paclitaxel-resistant cell xenografted tumor progression without side effects on body weight.
-
Animal Model:Female immune-deficient BALB/c nude mice (4 weeks old) were injected subcutaneously with Estradiol cypionate following with KHSRP knock-down MCF-7 cells (6 × 106 cells/mouse)[1].
-
Dosage:5 mg/kg, Estradiol cypionate (1.5 mg/kg)
-
Administration:i.p., once every three days (Estradiol cypionate, once every seven days) and then measured body weight and tumor volume.
-
Result:Induced no inhibitory activity in tumor growth without increase of lipid peroxidation product, aldehyde 4-HNE in KHSRP knock-down MCF-7 xenografted mice model
Chemical Information
-
CAS No. 186348-05-0
-
Molecular Weight 869.90
-
Formula C44H55NO17
-
SMILES
CC1(C)[C@@]2(O3)[C@@H](OC3=O)[C@H](OC([C@H](O)[C@@H](NC(OC(C)(C)C)=O)/C=C(C)/C)=O)C(C)=C1[C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@H]5C[C@@H]4O)([H])[C@@H]2OC(C6=CC=CC=C6)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)